University of Southern California

Research

RFA-DK-17-018 – Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R21 – Clinical Trial Optional)

Slots:                                                     Only one application per institution per year is allowed                 

Internal Deadline:                           Contact the Office of Research if interested.

LOI:                                                        30 days prior to the application due date

External Deadline:                          February 21, 2020, by 5:00 PM local time of applicant organization

Award Information:                        Type:  Grant

Estimated Number of Awards: The NIDDK intends to commit up to $1,000,000 per year in each of FYs 2018, 2019, and 2020 to fund up to 4 awards in each year.

Anticipated Amount: Application budgets are limited to $275,000 direct costs for two years with a maximum of $150,000 allowed in any year.

Submission Process:                     PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://app.wizehive.com/webform/USCgrants

Materials to submit:

Link to Award:                                  https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-17-018.html  

Who May Serve as PI:                    Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

Individuals receiving salary from any cooperative agreement awarded under RFA-DK-16-029 are not eligible to serve as PDs/PIs although they may serve as Senior/Key Personnel or Other Significant Contributors.

Purpose:

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD.  The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD.  However, the IBDGC’s current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains.  The purpose of this Funding Opportunity Announcement (FOA) is to expand the number of genes and range of IBD-related phenotypes and physiological domains under study by means of collaborations of the IBDGC with investigators with expertise complementary to that of their own members.  This FOA is intended to support highly exploratory studies which may require development and testing of novel experimental platforms or analytic methods.  Proposed studies must not duplicate studies either ongoing or already completed by the IBDGC.  Multi-site clinical trials will not be considered responsive to this FOA.

Activities appropriate for ancillary studies include the following, as well as many others not mentioned in this list:

    • Genetic analysis of IBD-related clinical and biological phenotypes in domains not previously investigated (e.g., intestinal remodeling and healing, enteric nervous system),
    • Application of novel methods for epigenomic, transcriptomic, proteomic, and metabolomic analyses of relevant tissue samples from recruited subjects, and systems biology analyses of the resulting data,
    • Analyses of the composition and activities of the intestinal microbiome of recruited subjects, with testing of hypotheses in gnotobiotic animals,
    • Screening of candidate genes and genetic variants in gut barrier, mucosal immune, and other physiological domains, using cultured cells, organoids, Drosophila, zebrafish, mice, and other assay platforms,
    • Analyses of the relationships among host genetic variation, intestinal microbiome composition and activity, and variation in the presentation, severity, natural history, and response to treatment of IBD,
    • Elucidation of regulatory interactions between DNA sites within the known IBD susceptibility loci and other genes, regardless of their genomic location, or
    • Reanalysis of existing data with novel analytic approaches to identify previously unknown susceptibility loci.

Visit our Institutionally Limited Submission webpage for updates and other announcements.